Year: 2008
Type: article
Abstract: Off-label prescribing is legal and common, but it is often done in the absence of adequate supporting data. Dr. Randall Stafford writes that although there is a strong rationale for greater FDA involvement in off-label use, it is moving toward relinquishing control in its new draft guidelines.
Source: New England Journal of Medicine
DOI: 10.1056/nejmp0802107
Author: Randall S. Stafford
Institutions: Stanford Medicine, Stanford University
Language: English
Subfield: Issues, ethics and legal aspects
Field: Nursing
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1997101969
